Two years follow-up of bleeding pattern during continuous HRT in recent postmenopausal women with uterine myomas

50 early postmenopausal women with one to four asymptomatic uterine myomas were treated for 24 months with: A) Tibolone, 2.5 mg/day; B) GEE, 0.625 mg/ day plus MPA, 5 mg/day. Amenorrhea incidence was higher in group A (82.2% o f the cycles) than in group B (73.0% of the cycles); irregular bleeding and irregular spotting incidences were higher in group B (21.6% and 5.4% of th e cycles, respectively) compared to group A (14.6% and 3.2% of the cycles, respectively). The mean bleeding and spotting lengths were not statisticall y different between the two groups. At the end of the study transvaginal US showed no significant change in leiomyoma size. Tibolone treatment seems t o be preferable compared to CEE-MPA continuous combined treatment (at the d oses tested here) in relation to the lower occurrence of irregular bleeding .